Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
376.66
+7.13 (+1.93%)
Streaming Delayed Price
Updated: 3:51 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
64
65
Next >
Is Amgen Stock a Buy?
↗
October 18, 2024
This biotech leader could be poised to rally higher.
Via
The Motley Fool
Looking Into Amgen's Recent Short Interest
↗
October 17, 2024
Via
Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
↗
October 14, 2024
The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
Via
Investor's Business Daily
In-Depth Examination Of 11 Analyst Recommendations For Amgen
↗
October 14, 2024
Via
Benzinga
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
↗
October 13, 2024
It is Fall clean up time. Sell lagging and sagging companies.
Via
Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
↗
October 11, 2024
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via
Benzinga
(AMGN) - Analyzing Amgen's Short Interest
↗
September 30, 2024
Via
Benzinga
Analyst Expectations For Amgen's Future
↗
September 25, 2024
Via
Benzinga
Market Whales and Their Recent Bets on AMGN Options
↗
September 24, 2024
Via
Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
↗
October 11, 2024
Income stocks can be wise additions to your portfolio in any market environment.
Via
The Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
↗
October 10, 2024
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.
Via
Benzinga
Topics
Stocks
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
↗
October 10, 2024
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade.
Via
Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
↗
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
↗
October 09, 2024
These longtime leading biotech stocks still have plenty of upside ahead.
Via
The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
↗
October 08, 2024
Investing in the most popular players in the space isn't the only valid approach.
Via
The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
↗
October 06, 2024
These dividend stocks are great picks as the fall season gets underway.
Via
The Motley Fool
Should You Buy the Dip on This Top Growth Stock?
↗
October 05, 2024
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
↗
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
↗
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
↗
October 02, 2024
Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge...
Via
Benzinga
Topics
Lawsuit
AskSlim Market Week - Friday, Sep. 27
↗
September 27, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
↗
September 27, 2024
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.
Via
Investor's Business Daily
Topics
Stocks
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
↗
September 26, 2024
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.
Via
Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
↗
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
↗
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
↗
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
↗
September 24, 2024
Regeneron filed an appeal after a court's decision, which was issued under seal.
Via
Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
↗
September 24, 2024
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.
Via
The Motley Fool
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
↗
September 23, 2024
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.
Via
Investor's Business Daily
Topics
Stocks
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
↗
September 23, 2024
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.
Via
Investor's Business Daily
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
64
65
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
